Intervention to Improve Continuity of Care in Lung Cancer Patients
Evaluation of a Multi-faceted Intervention to Improve Continuity of Care for Patients With Lung Cancer
1 other identifier
interventional
206
1 country
1
Brief Summary
Many authors have recognized the need to overcome the different barriers to continuity of cancer care, such as inadequate communication between specialists and family physicians (FP), insufficient information provided for the long-term follow-up care and difficulties to transfer back to FP the responsibility for cancer care at the end of treatments. This study aims to assess the effectiveness of a multi-faceted intervention to improve continuity of care for patients with lung cancer. Newly diagnosed lung cancer patients who have a FP will be randomly assigned to either the intervention group or to usual care and they will be followed at baseline, 3, 6, 9, 12, 15 and 18 months ( or until death for those with a survival of less than 18 months). The intervention comprises 4 components: 1) systematic appointments with FP at 3-month interval ; 2) transmission to FP of a standardized comprehensive summary before each appointment; 3) systematic transmission to the oncology team of patients' information resulting from FP visits; 4) development of a priority access to FP for cancer patients. In both groups, outcomes related to patients and to care processes will be measured at baseline and then after 3, 6, 9, 12, 15 and 18 months (or until death for those with a survival of less than 18months). Patients' principal family caregiver will be invited to participate to the study and they will complete questionnaires at baseline, at 6 months and at the end of the study. In addition, patients' FP will also be invited to complete a questionnaire at baseline and at the end of the study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable lung-cancer
Started Jun 2009
Longer than P75 for not_applicable lung-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2009
CompletedFirst Submitted
Initial submission to the registry
February 14, 2011
CompletedFirst Posted
Study publicly available on registry
July 8, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2014
CompletedApril 1, 2015
May 1, 2013
5.5 years
February 14, 2011
March 31, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mean score of perceived collaboration between FP and the oncology team (from 0 to 100)
Adaptation of Nielsen et al.'s questionnaire used to measure collaboration between health professionals (2003)
18 months
Secondary Outcomes (2)
Mean score of Global Quality of life
18 months
Mean score of Distress, Anxiety and Depression
18 months
Study Arms (2)
Exposed to the intervention
EXPERIMENTALPatients in the intervention arm will be exposed to a multi-faceted intervention to improve continuity of care; the intervention includes 4 components: 1) systematic appointments with FP at 3-month interval during the study period; 2) transmission to FP of a standardized comprehensive summary before each appointment; 3)systematic transmission to the oncology team of patients' information resulting from FP visits; 4) development of a priority access to FP for cancer patients
Usual care
NO INTERVENTIONInterventions
Periodic exchange of information between FP and oncology team and systematic appointments with FP at 3-month interval
Eligibility Criteria
You may qualify if:
- newly diagnosed adult patients with lung cancer, with a prognosis of at least 3 months
You may not qualify if:
- cognitive impairment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Laval Universitylead
- Canadian Cancer Society (CCS)collaborator
Study Sites (1)
Institut universitaire de cardiologie et pneumologie de Québec (IUCPQ)
Québec, Quebec, G1V 4G5, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michele Aubin, MD, PhD
Laval University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professeur
Study Record Dates
First Submitted
February 14, 2011
First Posted
July 8, 2011
Study Start
June 1, 2009
Primary Completion
December 1, 2014
Study Completion
December 1, 2014
Last Updated
April 1, 2015
Record last verified: 2013-05